

Article

N*-benzyl derivatives of long-chained 4-Amino-7-chloro-quinolines as inhibitors of pyocyanin production in *Pseudomonas aeruginosa

Ivana Aleksic, Jelena Jeremic, Dusan Milivojevic, Tatjana Ilic-Tomic,
Sandra Šegan, Mario Zlatovi#, Dejan M. Opsenica, and Lidija Senerovic

ACS Chem. Biol., **Just Accepted Manuscript** • DOI: 10.1021/acscchembio.9b00682 • Publication Date (Web): 24 Oct 2019

Downloaded from pubs.acs.org on October 25, 2019

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1
2
3 ***N*-benzyl derivatives of long-chained 4-Amino-7-chloro-quinolines as inhibitors of**
4
5 **pyocyanin production in *Pseudomonas aeruginosa***
6

7 *Ivana Aleksic*[†], *Jelena Jeremic*^{†#}, *Dusan Milivojevic*[†], *Tatjana Ilic-Tomic*[†], *Sandra Šegan*[†],

9
10 *Mario Zlatović*[§], *Dejan M. Opsenica*^{*†§}, *Lidija Senerovic*^{*†}
11
12
13

14 †Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode
15 Stepe 444a, 11010 Belgrade, Serbia
16
17

18 ‡Institute of Chemistry, Technology and Metallurgy, University of Belgrade, Njegoševa 12,
19 11000 Belgrade, Serbia
20
21
22

23 §Faculty of Chemistry, University of Belgrade, Studentski trg 12-16, 11158 Belgrade, Serbia
24
25

26 \$Center of Excellence in Environmental Chemistry and Engineering, ICTM, University of
27 Belgrade
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Pseudomonas aeruginosa is a leading cause of nosocomial infections that are becoming increasingly difficult to treat due to the occurrence of antibiotic resistant strains. Since *P. aeruginosa* virulence is controlled through quorum sensing, small molecule treatments inhibiting quorum sensing signaling pathways provide a promising therapeutic option. Consequently, we synthesized a series of *N*-octaneamino-4-aminoquinoline derivatives to optimize this chemotype's anti-virulence activity against *P. aeruginosa* via inhibition of pyocyanin production. The most potent derivative, which possesses a benzofuran substituent, provided effective inhibition of pyocyanin production ($IC_{50}=12 \mu M$), biofilm formation ($BFIC_{50}=50 \mu M$), and motility. Experimentally, compound's activity is achieved through competitive inhibition of PqsR, and structure-activity data was rationalized using molecular docking studies.

INTRODUCTION

Pseudomonas aeruginosa, an opportunistic pathogen, poses a significant public health threat in the context of nosocomial infections, particularly in individuals with wither cystic fibrosis (CF), or immunocompromised patients (*e.g.*, burn victims, cancer patients or patients with AIDS).¹ Specifically, such *P. aeruginosa* infections are associated with high morbidity and mortality rates resulting from strains of the bacteria that are resistant to nearly all available antibiotics.^{2, 3} Recently, the World Health Organization classified *P. aeruginosa* as one of the most critical pathogens requiring the development of novel therapeutics.⁴

In this regard, alternative strategies to treat antibiotic resistant bacteria do not directly affect vital bacterial processes (*e.g.*, cell wall synthesis), but rather, target virulence traits required to maintain pathogen presence in the host.^{5, 6} This tactic reduces evolutionary pathogen selection, thereby leading to a significant reduction in the development of resistance. With respect to the pathogenesis of *P. aeruginosa* infections, such treatment options afford the ability to inhibit the production of various cell-associated and secreted virulence factors that promote host invasion and tissue damage.⁷ Pyocyanin is one such important virulence factor, inducing cytotoxicity in different hosts by promoting the formation and release of reactive oxygen species.⁸⁻¹⁰ Another important virulence characteristic of *P. aeruginosa* stems from its ability to form biofilms, a thin layer of bacteria embedded in self-produced extracellular polymeric matrices.¹¹ Subsequently, and not surprisingly, biofilm formation results in chronic infection, and leads to persistent inflammation and tissue damage.¹²

Virulence factor production and biofilm formation are modulated through quorum sensing (QS).¹³ Therefore, interference with QS signaling is expected to repress the virulence factors' production which in turn leads to attenuated infections that can be cleared due to increased susceptibility to antibiotics.

1
2
3 Quorum sensing entails the production of extracellular signaling molecules referred to
4 as autoinducers (AI). The accumulation, detection, and response of bacteria to AIs regulates
5 virulence and the expression of virulence genes. The QS system in *P. aeruginosa* consists of
6 four interconnected and hierarchically organized signaling pathways: Las, Rhl, the PqsR-
7 controlled quinolone system (PQS), and the integrated QS system (IQS).¹⁴ Synthases LasI,
8 RhlI, and PqsABCDEH produce 3-oxo-C12-homoserine lactone (3OC12-HSL), *N*-
9 butyrylhomoserine lactone (C4-HSL), and 4-hydroxy-2-alkylquinolones (HAQs),
10 respectively, which are sensed by corresponding receptors LasR, RhlR, and PqsR. At high
11 concentrations AIs bind to specific receptors and activate target genes encoding for virulence
12 factors or synthases leading to the autoinduction of QS circuits. The LasR-3OC12-HSL
13 complex activates the expression of elastase, alkaline protease, lipase, *lasI* itself, and *rhlR*.
14 The RhlR-C4-HSL complex stimulates the production of rhamnolipids and biofilm
15 formation, while concomitantly repressing the PQS system. Synthase PqsABCDEH produces
16 2-heptyl-3-hydroxy-4-quinolone (PQS, Figure 1) and its precursor 2-heptyl-4-
17 hydroxyquinoline (HHQ, Figure 1), both of which are detected by the PqsR receptor.^{15, 16}
18 Formation of either the PqsR-PQS or the PqsR-HHQ complex triggers the transcription of the
19 *pqsABCDEH* operon, leading to the synthesis of PQS and HHQ. PqsR also regulates the
20 expression of *rhlI* and the production of several virulence factors, such as pyocyanin and
21 hydrogen cyanide, as well as biofilm formation. The expression of *pqsR* is activated by LasR,
22 but inhibited by RhlR.¹⁴ Hence, inhibitors of PqsR potentially reduce virulence factor
23 production and biofilm formation.^{17, 18} Moreover, the importance of HAQs for *P. aeruginosa*
24 pathogenicity has been demonstrated in experimental animal infection models¹⁹ and in CF
25 patients chronically infected with *P. aeruginosa*.²⁰ Since there is an urgent need for more
26 effective anti-*P. aeruginosa* therapeutics targeting the PQS pathway constitutes such a novel
27 drug development strategy.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

We have recently reported that long-chain 4-aminoquinolines (C12 derivatives, **2** and **3**, Figure 1) reduced biofilm formation and pyocyanin production in *P. aeruginosa* through interference with the PQS signaling pathway.¹⁷ Additionally, derivative **1** (C8 4-aminoquinoline) reduced 3OC12-HSL levels, but showed no influence on HAQ production, which resulted in reduced biofilm formation, and increased pyocyanin production. In this study we have chosen **1** for further derivatization to elucidate key structural parameters required to inhibit the PQS signaling pathway and improve inhibitory activity against pyocyanin and other virulence factor production.




Figure 1. Structures of HHQ, PQS, and selected QS inhibitors.

RESULTS AND DISCUSSION

Chemistry

















We have synthesized 26 derivatives of **1** according to the reactions presented in Scheme 1S. Parent compound **1** was obtained starting from 4,7-dichloroquinoline and neat 1,8-diaminooctane at 130 °C under inert atmosphere. Using various aryl- or alkyl-carbonyl compounds and NaBH₄ in MeOH, **1** was transformed into corresponding *N*-benzyl derivatives **7** – **25** and **30** or *N*-alkyl derivatives **26** - **29**. Derivatives **5** and **6** were prepared similarly to compound **1**, using corresponding amines under elevated temperature. The new derivatives were designed to investigate the influence of modifications of basic character (*i.e.*, alkyl- and acyl-substituent, respectively), steric demand (different alkyl-groups), and












1
2
3 electron-density of the terminal *N*-benzyl group on inhibition of various virulence factors
4
5 production. NMR spectra are provided in the Supporting Information 1 (SI1).
6

7 ***Pyocyanin and biofilm inhibition***

8
9
10 All compounds were first assayed for effects on pyocyanin production and biofilm
11 formation. The majority of compounds possessing substituted terminal aliphatic amino-
12 groups reduced pyocyanin levels in *P. aeruginosa* PA14, but with different efficacies (Table
13 1, SI1 Figure S1). The exceptions were imidazole containing derivative **14**, *N,N*-dimethyl
14 group substituted **26**, and *N*-isopropyl derivative **27**, which provided no activity against
15 pyocyanin production. Additionally, observed discrepancies included: 1) *N*-acyl derivative **5**,
16 which stimulated production of pyocyanin, suggesting that amine to amide transformation has
17 agonistic effects, and 2) C8 alkyl chain containing derivative **6**, which provided 80%
18 reduction in pyocyanin level compared to DMSO control. The most active compounds were
19 **11, 12, 18, 19, 20, and 23**, showing inhibition between 88% and 97%. Only four compounds,
20 **11, 16, 23, and 25**, effectively reduced biofilm formation, with BFIC₅₀ values (concentration
21 of compound that inhibited biofilm formation by 50%) of 50 μM (Table 1). Importantly, the
22 compounds showed no effect on bacterial growth at tested concentrations (SI1 Figure S1 and
23 S2), most of them having MIC values above 2 mM (SI1 Table S1).
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Effects of the compounds on pyocyanin (PYO) production, activities of QS receptors and biofilm formation in *Pseudomonas aeruginosa*.

Comp.	Structure	PYO ^a (%)	LasR ^a (%)	RhlR ^a (%)	PqsR ^a (%)	BFIC ₅₀ ^b (μ M)
1		112 \pm 5	121 \pm 10	90 \pm 2	68 \pm 2	100
7		42 \pm 10	105 \pm 2	70 \pm 3	72 \pm 5	125
8		33 \pm 15	70 \pm 3	76 \pm 4	32 \pm 4	200
9		47 \pm 8	85 \pm 2	85 \pm 5	60 \pm 4	n.a.
10		37 \pm 3	116 \pm 4	57 \pm 1	48 \pm 3	n.d.
11		12 \pm 4	80 \pm 4	40 \pm 2	7 \pm 0.5	50
12		8 \pm 2	120 \pm 5	73 \pm 6	25 \pm 2	n.a.
13		60 \pm 5	94 \pm 3	88 \pm 9	123 \pm 5	n.a.
14		93 \pm 5	107 \pm 1	95 \pm 4	46 \pm 6	n.a.
15		30 \pm 7	80 \pm 1	77 \pm 6	60 \pm 5	125
16		22 \pm 5	79 \pm 3	53 \pm 5	19 \pm 1	50
17		16 \pm 5	110 \pm 3	58 \pm 2	26 \pm 3	n.a.
18		8 \pm 4	133 \pm 5	59 \pm 3	31 \pm 3	125
19		7 \pm 2	104 \pm 3	65 \pm 2	27 \pm 2	n.a.
20		3 \pm 2	135 \pm 5	65 \pm 2	32 \pm 2	200
21		30 \pm 5	98 \pm 1	71 \pm 0.5	60 \pm 2	n.a.

22		55±10	100±1	70±3	62±1	125
23		11±4	100±3	52±4	25±1	50
24		40±4	141±5	80±6	45±4	n.a.
25		30±4	93±3	87±6	66±10	50
26		117±15	92±4	87±6	97±4	n.d.
27		94±6	112±1	76±5	54±4	125
28		35±7	117±4	67±2	54±2	n.a.
29		75±8	103±8	74±1	78±1	n.a.
30		41±6	103±3	87±3	64±3	n.a.
5		157±6	93±6	66±3	113±10	n.a.
6		21±3	128±6	58±1	9±1	n.a.

^aActivity of the compounds at 50 μ M concentration; Values are presented as mean \pm SD;

^bBFIC₅₀ – concentration of compound that inhibited biofilm formation by 50%; n.d. – not determined; n.a. – not active.

Previously we demonstrated that C12 4-aminoquinoline derivatives exhibited anti-QS activity through interference with the PQS signaling pathway, while **1** inhibited the production of 3OC12-HSL.¹⁷ To identify the biological target(s) of the novel derivatives presented herein, we evaluated their ability to competitively bind to QS receptors in the presence of exogenously provided autoinducers using *P. aeruginosa* biosensors (Table 1). *P. aeruginosa* PA14-R3, *P. aeruginosa* PAOJP2, and *P. aeruginosa* PAO1 Δ pqsA were used to measure LasR, RhlR, and PqsR activities, respectively. These biosensors cannot synthesize

1
2
3 respective AIs as their specific biosynthetic genes are deleted, and the light is detected only
4 when exogenously provided AI activates the corresponding receptor.²¹⁻²³ Most of the
5
6 compounds that reduced pyocyanin production by more than 70% also showed strong
7
8 inhibition of PqsR activity. The most prominent PqsR inhibition was observed for derivatives
9
10 **6** and **11**, which also reduced the activity of RhlR. Out of 26 tested compounds, only
11
12 derivative **13** acted as agonist on PqsR. This is an interesting finding given that its structural
13
14 isomer, **12**, acted as an antagonist. The good inhibitory activity of derivative **6** against
15
16 pyocyanin production and PqsR challenged the necessity for the functionalization of the side
17
18 chain. However, derivative **6** did not show inhibition of biofilm formation and had almost
19
20 30% agonistic effect to LasR. Another *N*-benzyl derivatives also showed good activity
21
22 against pyocyanin production and PqsR and to at least one of two other receptors and biofilm
23
24 formation such as **16** (4-chlorobenzyl) and **23** (4-nitrobenzyl), without agonistic activity.
25
26 Those results suggested that the presence of *N*-benzyl group is important for the activity of
27
28 this group of compounds.
29
30
31
32
33

34
35 We further examined the influence of *N*-phenylethyl group and the modification of
36
37 the side chain length on the compounds' activity. Derivatives with *N*-phenylethyl group (**30**
38
39 and **34**), as well as derivative **33** with shorter alkyl-chain did not show significantly changed
40
41 activity against pyocyanin production, biofilm formation, or interference with LasR or RhlR,
42
43 comparing to derivative **7** (Table 1 and SI1 Table S2). Only derivative **34** exhibited stronger
44
45 PqsR inhibition by 25%. Importantly, we observed significant rise in inhibitory activity
46
47 against all indications with derivative **35** (C12-*N*-benzyl), most likely as a result of elongated
48
49 alkyl-chain (SI1 Table S2).
50
51
52
53

54 Overall, the data presented in Table 1 suggests that the electronic properties of the
55
56 aryl-group tethered to the quinoline have no direct influence on PqsR activity or pyocyanin
57
58 production. Nevertheless, some structure-activity correlations are observed. For example,
59
60

1
2
3 halogen substituted derivatives are more active than other compounds – in general.
4
5 Additionally, *para*-substituted *N*-benzyl isomers are less active than their positional isomers,
6
7 as observed for **15** vs. **18** and **16** vs. **19** vs. **20**, suggesting that the position of the halogen is
8
9 important for activity. Similar correlations were obtained with MeO-substituted derivatives **9**
10
11 vs. **10**, as well as with benzothiophen derivatives **12** vs. **13**. Finally, the absence of distinct
12
13 differences between electron-rich and electron-poor *N*-benzyl derivatives suggests that non-
14
15 bonded interactions (*e.g.*, π - π stacking and weak π -hydrogen bonds) contribute significantly
16
17 to the inhibition of PqsR activity, and consequently, to pyocyanin production, but that
18
19 electronic within the aryl ring is not a major factor with respect to activity.
20
21
22
23
24
25

26 ***Quantitative structure property/activity relationship (QSPR and QSAR) and lipophilicity***
27 ***determination by reversed-phase thin-layer chromatography (RP-TLC)***
28
29

30
31 Lipophilicity and other structural parameters have a great impact on the overall
32
33 behavior of compounds in biological systems by influencing pharmacokinetics,
34
35 pharmacodynamics, and ADMET profiles, and are closely related to cellular membrane
36
37 permeability.²⁴ Short chain AHLs are freely diffusible, long chain AHLs and HHQ require
38
39 efflux pumps, while PQS is trafficked via membrane vesicles.²⁵⁻²⁷ In this study, to determine
40
41 the lipophilicities of the compounds, and to examine the quantitative structure properties or
42
43 quantitative structure-activity relationships (QSPR/QSAR) of the investigated compounds
44
45 with respect to the inhibition of pyocyanin production, we used reversed-phase thin-layer
46
47 chromatography (RP-TLC) and resulting retention parameters. This data is presented in
48
49 Supporting Information 2 (SI2 Tables S6-S8). Linear dependences between R_M values and
50
51 Vol % of organic modifier in the mobile phase were established (SI1 Tables S10-S12,
52
53 Graphic S2) and the R_M^0 were considered to be lipophilic parameters of the compounds.
54
55
56
57
58
59
60

1
2
3 Lipophilicity controls were also determined using interpolation and a calibration set of
4 the compounds with known $\log P$ values. The partition coefficients of the investigated
5 compounds were determined at pH 1, with mobile phase MeOH/H₂O/HCl=60/35/5 (Vol %),
6 and were presented as $\log D_{\text{exp}}$ (SI2 Table S9).
7
8
9

10
11
12 The obtained results provided valuable information on the influence of structural
13 modifications versus molecule lipophilicity (SI1). However, quantitative correlations of
14 either $\log D_{\text{exp}}$ or $\log D_{\text{calc}}$ (pH 7.4) (SI2 Table S9, Graphic S2) with the compounds' activities,
15 such as the inhibition of pyocyanin production or PqsR inhibition, were not observed.
16
17
18
19

20
21 Specifically, a QSAR model was constructed to quantify the contributions of the
22 structural features of derivatives with ability to inhibit pyocyanin production. However, the
23 predictive ability of the obtained model was not significant ($R^2_{\text{pred}}=0.561$), and therefore it
24 can only be interpreted qualitatively. Variables that had $\text{VIP}>1.1$ (Table 2, SI1 Table S4, SI2
25 Graphic S10) were considered as significant, and the highest contribution to activity against
26 pyocyanin production included SCIX3, SCIX4, SCIX5, CIQPlogS, WPSA, and mol MW.
27 These results show that descriptors related to solvation, water solubility, and molar mass
28 contributed more to the inhibition of pyocyanin production than descriptors related to
29 lipophilicity, *e.g.*, QPlogPo/w and $\log D$. Thus, the low influence of lipophilicity and the
30 absence of a quantitative correlation of either $\log D_{\text{exp}}$ or $\log D_{\text{calc}}$. [QPlogPo/w, $\log D_{\text{calc}}$ (pH
31 1.0) and $\log D_{\text{calc}}$ (pH 7.4), SI2 Table S9] with the inhibition of pyocyanin synthesis may
32 suggest that the investigated compounds are transported through the cell membrane by
33 facilitated transport rather than passive diffusion, especially since they are ionized at
34 physiological pH.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. The statistical performance of QSPR models correlating molecule descriptors with the inhibition of the pyocyanin synthesis in *Pseudomonas aeruginosa*^a.

	<i>Statistical performance of the model</i>	<i>Structural descriptors included in PLS model^b</i>
<i>log(%PYO), 50 μgmL⁻¹</i>	RMSEC=0.172, RMSECV=0.248, RMSEP=0.326, R ² _{cal} =0.827, R ² _{CV} =0.654, R ² _{pred} =0.561 PLS1: 35.28% and 75.03% PLS2: 20.30% and 7.64%	ALOGP2 (-), ACIX2 (+), SCIX3 (-), SCIX4 (-), SCIX5 (-), TCI3 (-), TCI4 (-), CIQPlogS (+), PISA (-), QPlogKhsa (-), QPlogPo/w (-), WPSA (-), mol MW (-), logD (-)

^aGraphics that illustrate obtained PLS models for contribution of structural descriptor to molecular lipophilicity and inhibition of pyocyanin production are provided in Graphic 9S.

^bFor abbreviation definitions and complete list of molecular descriptors see SI2.

Anti-virulence activity of selected compounds

Based on their activity against pyocyanin production and biofilm formation, and inhibition of PqsR, derivatives **11** and **12** were selected to further investigate how *N*-benzyl derivatization of **1** affects other QS-regulated virulence characteristics in *P. aeruginosa*. Compound **11** showed inhibitory activity against both pyocyanin production (concentration of compound that inhibited pyocyanin production by 50%, IC₅₀=12 μM) and biofilm formation, while **12** strongly inhibited pyocyanin production (IC₅₀=25 μM), but only weakly inhibited biofilm formation (Table 1). Compounds **1** and **11** dose-dependently reduced the formation of biofilms in concentrations up to 100 μM, and this effect was not increased by increasing dose (Figure 2A), while **12** showed only 20% reduction in biofilm formation, even at the highest applied concentration. Consistently, fluorescence microscopy showed that upon treatment of *P. aeruginosa* PAO1 with **11**, only small viable cell aggregates could be observed, while extracellular polymeric matrix containing fluorescently stained extracellular DNA²⁸ was less visible than in samples treated with **1**, **12** or DMSO (Figure 2B).





Figure 2. Effects of the compounds on biofilm formation. (A) Dose dependent inhibition of biofilm biomass measured by CV staining. All values were plotted relative to a DMSO-treated control and presented as mean \pm SD. * $P < 0.05$, ** $P < 0.001$, *** $P < 0.0001$. (B) Fluorescent micrography of *P. aeruginosa* formed in the presence of 0.1% DMSO or 50 μ M compound. Biofilms were grown for 24 h and stained with Syto9 (green) and PI (red). The scale bar represents 10 μ m.

Additional virulence characteristics contributing to *P. aeruginosa* pathogenicity involve three types of motility, swimming, swarming, and twitching, which enable the bacteria to colonize different environments, and the production of elastases (hydrolytic enzymes that affect host cell proteins in infected tissues and facilitate bacterial invasion and growth).^{29, 30} Swarming and twitching motility, and elastase production are QS-regulated virulence characteristics, while swimming is QS-independent.³¹⁻³³ At concentrations of 50 μ M, compounds **11** and **12** completely abolished twitching, while swarming and swimming were inhibited by 40% to 60% (Figures 3A and SI1 Figure S3). Parent compound **1** exhibited moderate effects on swarming and twitching motility, with inhibition rates of 30%, while swimming was stimulated by 80%. On the other hand, at a concentration of 50 μ M, derivate **1**

1
2
3 inhibited elastase production by 50%, while in the presence of **11** and **12** elastase activity was
4
5 reduced by 35% and 30%, respectively (Figure 3B).
6
7



24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Figure 3. Effects of selected compounds on *P. aeruginosa* (A) motility and (B) elastase production. All values are plotted relative to a DMSO-treated control and presented as mean \pm SD. * $P < 0.05$, ** $P < 0.001$, *** $P < 0.0001$.

47
48
49
50
51
52
53
54
55
56
57
58
59
60

The similar anti-virulence activities of **11** and **12** are likely due to their structural similarity, since their additional heterocyclic rings are sterically comparable, and both are electron enriched and could be involved in similar types of non-bonded interactions with the potential target. Although derivatives **11** and **12**, compared to parent compound **1**, showed improved anti-virulence activity, they both were cytotoxic in *in vitro* and *in vivo* assays (SI1 Table S1, Figure S4).

To closely examine the mechanism(s) responsible for the anti-QS activity of these derivatives, *P. aeruginosa* biosensor strains were incubated with increasing concentrations of selected compounds in the presence of exogenously provided natural AIs. Quorum sensing inhibitor Furanone C-30³⁴ was used as a positive control (SI1 Figure S5). Compound **1** was only effective against PqsR activity, decreasing its functionality up to 35% depending on the dose (Figure 4). Derivatives **11** and **12** dose-dependently inhibited RhlR and PqsR.

Compound **12** showed considerable stimulatory effect on LasR at concentrations up to 100 μM , while **11** significantly stimulated LasR activity only at 25 μM . Since **11** and **12** exhibited more prominent repressive effect on PqsR (IC_{50} values of 25 μM and 30 μM , respectively) than RhlR (IC_{50} value of 40 μM for **11**; IC_{50} not determined for **12** because of growth reduction at concentrations above 100 μM), and considering that the PQS system has a positive effect on Rhl system,³⁵ it is likely that the primary target of these compounds is the PQS system.




Figure 4. Effects of select compounds on the activity of QS receptors detected by bioluminescence measurements. All values are plotted relative to a DMSO-treated control and presented as mean \pm SD.

We further evaluated the effects of the compounds on the production of AIs using the same *P. aeruginosa* biosensors, but exogenously provided AIs extracted from *P. aeruginosa* PAO1 cultures upon growth in the presence of 50 μM of select compounds. In the presence of **11** the quantity of HAQs in *P. aeruginosa* PAO1 culture supernatant was reduced by 60%, the amount of 3OC12-HSL was almost doubled, while C4-HSL level was not significantly changed (Table 3). Compound **12** inhibited only HAQ production, while **1** moderately reduced the amount of 3OC12-HSL, but slightly stimulated production of HAQs. These results confirmed that the primary target of **11** and **12** is the PQS signaling pathway via showing that inhibition of the PQS signaling pathway is required for successful inhibition of pyocyanin production. Moreover, 3OC12-HSL levels are in accordance with observed

stimulation of LasR (Table 1, Figure 4), and unchanged levels of C4-HSL, in spite of obvious inhibition of RhlR, could be explained by additional control of C4-HSL production *via* the LasR/LasI system.^{14, 36}

Table 3. Production of autoinducers by *P. aeruginosa* PAO1 in the presence of 50 μ M compounds measured using specific *P. aeruginosa* biosensors.

Compound ^a	Production (%)		
	C4-HSL	3OC12-HSL	PQS/HHQ
1	87 \pm 1	74 \pm 10	110 \pm 9
11	89 \pm 3	191 \pm 17	39 \pm 2
12	91 \pm 5	93 \pm 15	61 \pm 9

^aValues are given relative to a DMSO-treated control and are average of three independent experiments \pm SD.

Quantitative Real Time RT-PCR analysis was performed on total mRNA isolated from *P. aeruginosa* PAO1 cultured with select compounds to investigate their effects on the level of receptors' (*lasR*, *rhlR*, and *pqsR*) and autoinducer synthases' (*lasI*, *rhlI*, and *pqsA*) transcription. Evaluating changes greater than two-fold, we found that the compounds affected neither the receptors' nor synthases' transcription levels (SI Figure S6). Therefore, reduced levels of HAQs in the supernatants of **11** and **12** treated *P. aeruginosa* cultures could be a consequence of reduced functionality of PqsR and/or the enzymes required for quinolone biosynthesis.

Taken together, these results show that inhibition of pyocyanin occurs as a result of the antagonistic binding of the compounds to PqsR.³⁵ The activity of **11** and **12** against biofilm formation and elastase production could be a consequence of their additional inhibition of RhlR, while significant reduction of elastase production by **1** could be explained by its interaction with Las signalling pathway and reduced levels of 3OC12-HSL³⁷ Different

1
2
3 effects of the compounds on the three QS signaling pathways involving agonistic or
4 antagonistic activities, and the interconnection between the pathways resulted in overall
5
6 different manifestation of *P. aeruginosa* virulence characteristics.
7
8

9 10 ***Docking Simulations***


11
12 Structure-based docking simulations were performed to rationalize the observed
13 inhibitory activities for PqsR of the most active derivatives: **6**, **11** and **12**, and the parent
14 compound **1**. Derivative **6** inhibits PqsR activity by more than 90% (Table 1), and comprises
15 structural fragments of synthesized derivatives, including a 4-aminoquinoline moiety, the *n*-
16 alkyl side chain of HHQ, PQS and synthetic antagonist **3-NH₂-7Cl-C9-QNZ**.³⁸
17
18
19
20
21
22

23
24 The docking simulation results indicated that the quinoline rings of **1**, **6**, **11**, and **12**
25 occupy the same hydrophobic pocket of the receptor (Figure 5, SI1 Figure S8, S9, S12, S14).
26 However their orientations depended on additional interactions with surrounding protein
27 residues. For **1**, the quinoline core achieved a NH- π interaction with Phe221 (2.53 Å), two
28 halogen-H interactions with the side chains of Ser196 (OH-group, 2.85 Å) and the main chain
29 NH of Leu197 (2.90 Å) (Figures 5A, SI1 Figure S8), and a strong H-bond with the main
30 chain carbonyl groups of Asn206 and Arg209.
31
32
33
34
35
36
37
38

39
40 The modes of interaction for **11** and **12** with PqsR were almost identical (Figures 5B,
41 SI1 Figures S8 and S9). However, the side chains of these compounds were oriented opposite
42 to **1** due to the steric demands of their terminal *N*-substituents, and were additionally
43 stabilized by hydrophobic interactions with the side chain residues of Leu207 and Ile263.
44
45 Additional interactions with PqsR were: a) a H-bond between the protonated terminal amino-
46 group and the side chain carboxylate of Glu259 (**11** 1.59Å and **12** 1.60Å), b) moderate H-
47 bonds between NH-C(4) and the main chain carbonyl of Leu207 (**11** 2.52Å and **12** 2.92Å), c)
48 halogen-H bond interactions with the side chain OH-group of Ser196 and the main chain NH
49
50
51
52
53
54
55
56
57
58
59
60

of Leu197, and d) π -H and π - π interactions with the main chain NH of Glu259 and Tyr258, respectively, and benzofuran/benzothiophene.

Derivative **6** binding positioned the alkyl chain downward, compared to the side chains of **11** and **12** (Figures 5C and SI1 Figure S9), and therefore constitutes a third mode of ligand-PqsR bonding. Additionally, **6** formed a H-bond between NH-C(4) and the carbonyl of the main chain of Leu207 (2.36 Å).



1
2
3 **Figure 5.** Docking of select compounds in the binding site of PqsR (PDB code 4JVI), with
4 key amino acid residues emphasized in stick. A) Compound **1** (orange carbons). B)
5 Compound **11** (cyan carbons) and **12** (orange carbons) binding predictions. C) Compound **6**
6 (purple carbons) binding prediction. For full ligand interaction diagrams see SI1 Figures S8 –
7
8
9
10
11
12
13 S9.

14 Moreover, modeling showed that the derivatives placed their quinolone rings into the same
15 hydrophobic pocket as natural PqsR ligands, and synthetic antagonist **3-NH₂-7Cl-C9-QNZ**³⁸
16 (SI1 Figures S10-S14). These three molecules also achieved additional interactions: a)
17 hydrophobic interactions between their alkyl chains and the same region as derivative **6** (SI1
18 Figure S9), and b) a H-bond with the main chain carbonyl group of Leu207, formed *via* N(1)-
19 H of HHQ (2.83Å), C(3)-OH of PQS (2.31Å) or N(3)-NH₂ for **3-NH₂-7Cl-C9-QNZ** (1.93Å).
20
21
22
23
24
25
26
27
28

29 These results support the experimental findings that **6**, **11**, and **12** inhibit PqsR by
30 competing for the same binding site as natural ligands HHQ and PQS. We believe that the
31 Glide emodel is more appropriate for comparison with the ligand-PqsR bonding mode than
32 the GlideScore due to structural similarities of the compounds³⁹. The Glide emodel values
33 (SI1 Table S5) were completely in accordance with observed interactions in the presented
34 models. However, they did not correlate with the observed inhibitory activities of examined
35 compounds, native AIs, and **3-NH₂-7Cl-C9-QNZ**. This could be due to limited estimation of
36 the entropy gain or loss upon binding. Second, observed scores were obtained through
37 modeling with a sole receptor and approximation that of the entirety of the tested compound
38 is present, which is not necessarily the case in biological systems. And finally, inhibition of
39 PqsR activity comprises successive steps of conformational changes, including association of
40 active complexes into dimers and further to tetramers, which makes the process demanding
41 for modeling.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The docking models revealed that most active compounds (**6**, **11**, and **12**) have
4 different modes of receptor binding, which provide opportunities for developing quinoline-
5 based derivatives in different directions to obtain more active compounds.
6
7
8
9

10 Taken together, the models provide insights into possible interactions between PqsR
11 and the derivatives presented herein, and may serve as to generate hypotheses for further,
12 synthetic structural improvements. Importantly, the described model for the derivatives, and
13 previous results for HHQ, PQS, and **3-NH₂-7Cl-C9-QNZ**,³⁸ revealed the importance of an H-
14 bond with Leu207, suggesting that distance between ligand and Leu207 could be a measure
15 of interaction strength.
16
17
18
19
20
21
22
23

24 Based on this general model, the proposed inhibition mechanism of PqsR with
25 quinoline-based derivatives involves: a) occupation of a hydrophobic pocket with quinoline
26 rings, formation of an H-bond with Leu207, and establishment of the above defined
27 interactions of the compound side chains with the main or the side chain groups of
28 surrounding protein residues, thereby preventing the binding of native AI's to the active site,
29 and thus activation of PqsR monomers, b) conformational changes of PqsR as a consequence
30 of established interactions, and in the case of **11** and **12**) position of the benzofuran or
31 benzothiophene rings additionally prevents dimerization to active AQ-PqsR complexes and
32 further formation of tetramers (and binding to DNA)⁴⁰. A similar process to the latter was
33 observed by modeling of structurally unrelated PqsR inhibitor **M64**, and experimentally
34 confirmed by the X-ray structure of PqsR in complex with **M64**.⁴¹ Hence, simple insertion of
35 quinoline rings and long alkyl-side chains into the active site is not sufficient for inhibition of
36 PqsR, since many 2-alkyl-7-halogenquinolones showed agonistic activity³⁸ implying that
37 additional conformational changes are necessary for inhibitory activity.⁴¹ Considering the
38 proposed models, significantly stronger interactions and improved inhibition of PqsR with
39 quinoline-based derivatives versus **3-NH₂-7Cl-C9-QNZ** and congeners is expected.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 However, the lower inhibitory activity of the tested quinoline derivatives could be the result
4 of their probable lower bioavailability in comparison to **M64** and **3-NH₂-7Cl-C9-QNZ**. This
5 is in line with the high contribution of descriptors related to solvation and solubility, thus
6 suggesting that active compounds most likely require facilitated transport through cell
7 membranes.
8
9

17 CONCLUSIONS

19 In summary, we have developed a new series of quinoline derivatives as antagonists
20 of *P. aeruginosa* native AIs, with a broad anti-virulence activity established through
21 interference with distinct QS signaling pathways. We showed that most of the compounds
22 having *N*-benzyl substituted aliphatic terminal amino-group were able to reduce pyocyanin
23 level through PqsR inhibition. The most active inhibitors of pyocyanin production and PqsR
24 activity were **11** and **12**, having benzofuran and benzothiophene substituents, respectively.
25 Both **11** and **12** significantly reduced *P. aeruginosa* motility, suppressed production of
26 HAQs, and showed moderate effects on elastase production, while **11** additionally reduced
27 biofilm formation.
28
29

31 The results of QSAR analysis indicated that inhibition of pyocyanin production and
32 PqsR activity simultaneously depended on several structural parameters, and that the
33 solvation, connectivity, and aqueous solubility of the examined compounds have strong
34 influence on activity. A lower contribution of lipophilicity and the absence of its quantitative
35 correlation with the inhibition of pyocyanin production may suggest that the compounds are
36 transported by efflux pumps rather than by passive diffusion. Molecular modeling studies
37 showed that the quinoline rings of the examined derivatives occupied the same hydrophobic
38 pocket of the PqsR receptor and formed critical H-bonds with Leu207, as observed for native
39 AIs, while achieving additional interactions with surrounding protein residues. Specifically,
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the compounds engaged in additional hydrophobic interactions through their *N*-substituted
4 amino-alkyl chains, and hydrophobic and π -interactions through their alkyl chains and *N*-
5 benzyl substituents, respectively, and H-bonds or salt bridges via the protonated amines of
6 their aliphatic amino groups. The binding models propose three different modes of interaction
7 by the derivatives with PqsR, depending on the structure of compound side chain, and offers
8 the possibility for the design and development of more potent PqsR inhibitors.
9
10
11
12
13
14
15
16
17
18

19 **METHODS**

20 **Chemistry**

21
22
23 Melting points were determined on a Boetius PMHK apparatus and were not corrected.
24
25 Reactants were obtained from various suppliers and used without further purification. IR
26 spectra were recorded on a Perkin-Elmer spectrophotometer FT-IR 1725X. ^1H and ^{13}C NMR
27 spectra were recorded on a Bruker Ultrashield Advance III spectrometer (at 500 and 125
28 MHz, respectively) employing indicated solvents using TMS as the internal standard.
29
30 Chemical shifts are expressed in ppm (δ) values and coupling constants (J) in Hz. ESI-MS
31 spectra were recorded on a LTQ Orbitrap XL instrument in positive ion mode by direct
32 injection. Samples were dissolved in MeOH (HPLC grade purity). Selected values were as
33 follows: capillary voltage 49 V, capillary temp 275 °C, vaporizer temp 60 °C, spray voltage
34 4.2 kV, resolution (at m/z 400) 30000. TOF-MS spectra were recorded on a 4800 Plus
35 MALDI TOF/TOF Analyzer, Applied Biosystems, US instrument Positive ion mode (fixed
36 laser intensity 4280), with $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ gradient with 0.2% HCOOH as the carrying solvent
37 solution. Samples were dissolved in MeOH (HPLC grade purity) mixed with CHCA (α -
38 Cyano-4-hydroxycinnamic acid) MALDI matrix (5 mg/mL in 50% acetonitril (v/v)). Internal
39 calibrants: Azithromycin and Azithromycin fragments (m/z 156-749). Dry-flash
40 chromatography was performed on 40-63 μm and thin-layer chromatography (TLC) was
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 performed on precoated Merck silica gel 60 F254 and RP-18 F254 plates using UV light,
4
5 cerium-ammonium molybdate (CAM) and Co(II)-thiocyanate for chromatogram visualization.
6
7 Compounds were analyzed for purity (HPLC) using an Agilent Technologies 1260 liquid
8
9 chromatograph equipped with quaternary pump (G1311B), injector (G1329B), 1260 ALS,
10
11 TCC 1260 (G1316A), and detector 1260 DAD VL+ (G1315C). For data processing, LC
12
13 OpenLab CDS ChemStation software was used. The HPLC purity of all synthesized
14
15 compounds were >95% with exception of **30** which shows 87% and 88.45% purity.
16
17

18
19 **Microbial strains and growth conditions.** *Pseudomonas aeruginosa* PAO1 NCTC 10332
20
21 and *P. aeruginosa* PA14 were used in this study. Bacteria were grown in Luria Bertani (LB)
22
23 broth on a rotary shaker at 180 rpm at 37 °C.
24
25

26 **Antimicrobial susceptibility tests for planktonic cells.** The minimum inhibitory
27
28 concentrations (MIC) of compounds were determined according to standard broth
29
30 microdilution assays recommended by the Clinical and Laboratory Standards Institute (M07-
31
32 A9) (CLSI, 2012). Stock solutions of the compounds were prepared in DMSO (200 mM).
33
34 The highest tested concentration of any compound was 4 mM. The inoculums were 10⁵
35
36 colony forming units (CFU) mL⁻¹. The MIC value corresponded to the lowest concentration
37
38 that inhibited the visual growth after 20 h at 37 °C. DMSO was used for the growth control at
39
40 the same concentration (up to 2%, v/v) as in the treatments. The assay was carried out in
41
42 triplicate, and repeated twice.
43
44
45

46 **Static biofilm formation inhibition assay.** Biofilm quantification assays were performed in
47
48 96-well microtiter plates using a crystal violet (CV) method to stain adherent cells.⁴³ Biofilms
49
50 formed for 24 h at 37 °C in the presence or absence of compounds were washed and adherent
51
52 cells stained with 0.1% (v/v) CV. Each biofilm formation assay was performed in six wells
53
54 and repeated at least three times.
55
56
57
58
59
60

1
2
3 **Pyocyanin assay** was performed with *P. aeruginosa* PA14 as reported.⁴⁴ Pyocyanin in the
4 supernatant was quantified using a UV–vis spectrophotometer Ultrospec 3300pro (Amersham
5 Biosciences, USA) at 695 nm. The experiment was performed in triplicate and repeated at
6
7
8
9
10 least three times.

11
12 **Elastase assay.** The elastolytic activity in the supernatants of cultures incubated with the
13 compounds or 0.1% DMSO was determined using the Elastin Congo Red (ECR) method.⁴⁵ A
14 100 µl aliquot of the cell-free supernatant was added to 900 µl of ECR buffer containing 5 mg
15 of ECR (Sigma, Munich, Germany). The mixture was incubated on a rotary shaker for 12 h at
16
17 37 °C. Insoluble ECR was removed and the absorption was measured at 485 nm. The
18
19 experiments were performed in triplicate and repeated three times.

20
21
22
23
24
25 **Motility assays.** A swarming assay was performed on M8 plates containing 0.6% agar and
26 either compound or DMSO. Plates were inoculated with 2.5 µL of the diluted *Pseudomonas*
27 cultures (OD₆₂₀ of 0.2), and the phenotype was observed and measured after 16 h incubation
28
29 at 37 °C.⁴⁶

30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Swimming motility was measured according to a previously described protocol.⁴⁷ Overnight cultures were diluted to OD₆₂₀ of 0.2 and point-inoculated using toothpick bacteria onto M8 plates (5 g L⁻¹ Na₂HPO₄, 3 g mL⁻¹ KH₂PO₄, 0.5 g L⁻¹ NaCl, 0.2% glucose, 0.5% casaminoacids and 1 mM MgSO₄) containing 0.3% (w/v) agar and the compound. The plates were incubated for 18 h at 37 °C. The distance of colony migration around the inoculation site was evaluated by measuring the diameter of the covered areas.

Twitching motility was evaluated as previously described.⁴⁸ Overnight *Pseudomonas* cultures were stabbed with a toothpick into LB plates supplemented with 1% agar and the compound, and incubated at 37 °C for 20 h followed by additional incubation for 72 h at 25 °C. Bacterial migration along the plastic surface was detected and measured by CV (2%, (v/v)) staining after removing the agar from the plate.

1
2
3 **Interference of the compounds with QS pathways.** Overnight cultures of biosensors *P.*
4 *aeruginosa* PA14-R3 ($\Delta lasI PrsA::lux$),²¹ PAOJP2/pKD-*rhlA* ($\Delta rhlA PrhA::lux$),²² and *P.*
5 *aeruginosa* PAO1 $\Delta pqsA$ (CTX $lux::pqsA$)²³ were diluted to $OD_{600}=0.045$, and incubated
6 with 4-AQ derivatives in the presence of 5 μM of specific autoinducers 3OC12HSL, C4-HSL
7 and HHQ, respectively. Cell density (OD_{620}) and bioluminescence (light counts per second,
8 LCPS) were simultaneously measured after 4 h of incubation using Tecan Infinite200
9 multiplate-reader (Tecan Group Ltd., Switzerland). Luminescence values were normalized
10 per cell density. The assays were carried out in quadruplicate and repeated three times.
11
12
13
14
15
16
17
18
19
20
21

22 **Fluorescent microscopy.** Overnight cultures of bacteria were diluted to 5×10^7 CFU mL^{-1} in
23 LB and 2 mL were added per well of 6-well microtiter plates containing plastic cover slips in
24 the presence of DMSO (0.1%) or $BFIC_{50}$ concentrations of active compounds. After 24 h,
25 biofilms were washed with 0.9% NaCl and stained with 2.5 μM SYTO9 green fluorescent
26 dye and 2.5 μM propidium iodide (PI) red fluorescent dye (LIVE/DEAD® BacLight™
27 Bacterial Viability Kit, Thermo Fisher Scientific, Waltham, MA, USA). Cells were observed
28 under a fluorescence microscope (Olympus BX51, Applied Imaging Corp., San Jose, USA)
29 under 40 \times magnification.
30
31
32
33
34
35
36
37
38
39

40 **Molecular modeling.** Modeling of ligand-receptor interactions was performed using modules
41 in Schrödinger Suite 2017-3 (Schrödinger, LLC, New York, NY, 2017). The structure of
42 PqsR was generated from X-ray crystal structure PDB code 4JVI.³⁸ The protein was prepared
43 for docking simulations using the Protein Preparation Wizard (Schrödinger Suite 2017-3,
44 Protein Preparation Wizard). The DNA molecule, second protein chain, ligand, and water
45 molecules were removed, and the final structure achieved by minimization of hydrogen
46 atoms with heavy atoms restrained. Structures of examined compounds were constructed
47 using Maestro (Maestro, Schrödinger, LLC, New York, NY, 2017). The best conformations
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 were selected using Conformational search from MacroModel (OPLS_2005 force field with
4 water as a solvent (MacroModel, Schrödinger, LLC, New York, NY, 2017)).
5
6

7
8 Compound conformers were generated using a mixed torsional/low-mode sampling
9 method, with an energy window of 10 kJ/mol. Every generated conformation was subjected
10 to energy minimization using a Polak-Ribiere Conjugate Gradient method with 2500
11 iterations or 0.05 convergence thresholds (whichever was achieved first) and duplicates were
12 removed. Best conformers of every structure were used for generating molecular descriptors
13 for QSAR calculations using QikProp module (QikProp, Schrödinger, LLC, New York, NY,
14 2017). For docking in the protein, all structures were used as double protonated on the N-
15 atom of the quinoline ring, and the terminal amino group, in accordance with the
16 experimental conditions of the PqsR inhibition assay (Epik, Schrödinger, LLC, New York,
17 NY, 2017). Docking simulations were performed in Glide (Glide, Schrödinger, LLC, New
18 York, NY, 2017), with standard precision (SP), enhancing the planarity of conjugated π
19 groups, and post-docking minimization.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 **Statistical analysis.** The results were analyzed by Student's t-test using SPSS version 20
36 software. A P-value lower than 0.05 was considered statistically significant.
37
38
39
40
41

42 ASSOCIATED CONTENT.

43
44 Supporting Information. This material is available free of charge via the internet at
45 <http://pubs.acs.org>.
46
47

48
49 **Supporting Information 1.** *In vitro* and *in vivo* toxicity and qRT-PCR assays, multivariate
50 statistical analysis PCA and PLS modeling, molecular modeling, ligand-receptor interaction
51 diagrams, synthesis and spectral data, TLC for lipophilicity determination, copies of NMR
52 spectra, and HPLC purity chromatograms.
53
54
55
56
57
58
59
60

1
2
3 **Supporting Information 2.** List of molecular descriptors, compounds molecular descriptors
4 data matrix, details of PLS models: RM0 MeOH, RM0 Diox, RM0 AC, log PYO, and logD.
5
6
7
8
9

10 **AUTHOR INFORMATION**

11 **Corresponding Authors**

12
13 *E-mail: seneroviclidija@imgge.bg.ac.rs

14
15 *E-mail: dopsen@chem.bg.ac.rs

16 **Present Addresses**

17
18 #Center for Structural Systems Biology, Notkestrasse 85, 22607, Hamburg

19 **Notes**

20
21 The authors declare no competing financial interest.

22 **Author Contributions**

23
24 All authors contributed equally to the preparation of the manuscript. All authors have given
25 approval to the final version of the manuscript.

26 **ACKNOWLEDGMENT**


27
28 This study was funded by the International Centre for Genetic Engineering and
29 Biotechnology, Italy (Grant No. CRP16-02) and the Ministry of Education, Science and
30 Technological Development, Republic of Serbia (Grants Nos. 173048 and 172008). We
31 gratefully acknowledge M. Spasić, University of Belgrade Faculty of Chemistry, for
32 assistance with the compound synthesis, and L. Leoni, University Roma Tre, Italy, for
33 providing *P. aeruginosa* biosensor strains. The authors acknowledge the support of the FP7
34 RegPot project FCUB ERA GA No. 256716. The EC does not share responsibility for the
35 content of the article.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Moradali, M. F., Ghods, S., and Rehm, B. H. (2017) *Pseudomonas aeruginosa* Lifestyle: A Paradigm for Adaptation, Survival, and Persistence. *Front. Cell. Infect. Microbiol.* *7*, 39.
2. Aloush, V., Navon-Venezia, S., Seigman-Igra, Y., Cabili, S., and Carmeli, Y. (2006) Multidrug-resistant *Pseudomonas aeruginosa*: risk factors and clinical impact. *Antimicrob. Agents Chemother.* *50*, 43-48.
3. Carmeli, Y., Troillet, N., Eliopoulos, G. M., and Samore, M. H. (1999) Emergence of antibiotic-resistant *Pseudomonas aeruginosa*: comparison of risks associated with different antipseudomonal agents. *Antimicrob. Agents Chemother.* *43*, 1379-1382.
4. World Health Organisation. <https://http://www.who.int/en/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed> (April 08, 2019).
5. Defoirdt, T. (2018) Quorum-Sensing Systems as Targets for Antivirulence Therapy. *Trends Microbiol.* *26*, 313-328.
6. Wagner, S., Sommer, R., Hinsberger, S., Lu, C., Hartmann, R. W., Empting, M., and Titz, A. (2016) Novel Strategies for the Treatment of *Pseudomonas aeruginosa* Infections. *J. Med. Chem.* *59*, 5929-5969.
7. Gellatly, S. L., and Hancock, R. E. (2013) *Pseudomonas aeruginosa*: new insights into pathogenesis and host defenses. *Pathog. Dis.* *67*, 159-173.
8. Liu, G. Y., and Nizet, V. (2009) Color me bad: microbial pigments as virulence factors. *Trends Microbiol.* *17*, 406-413.
9. Winstanley, C., and Fothergill, J. L. (2009) The role of quorum sensing in chronic cystic fibrosis *Pseudomonas aeruginosa* infections. *FEMS Microbiol. Lett.* *290*, 1-9.
10. Lau, G. W., Hassett, D. J., Ran, H., and Kong, F. (2004) The role of pyocyanin in *Pseudomonas aeruginosa* infection. *Trends Mol. Med.* *10*, 599-606.
11. Flemming, H. C., Wingender, J., Szewzyk, U., Steinberg, P., Rice, S. A., and Kjelleberg, S. (2016) Biofilms: an emergent form of bacterial life. *Nat. Rev. Microbiol.* *14*, 563-575.
12. Hoiby, N., Bjarnsholt, T., Givskov, M., Molin, S., and Ciofu, O. (2010) Antibiotic resistance of bacterial biofilms. *Int. J. Antimicrob. Agents* *35*, 322-332.
13. Whiteley, M., Diggle, S. P., and Greenberg, E. P. (2017) Progress in and promise of bacterial quorum sensing research. *Nature* *551*, 313-320.
14. Papenfort, K., and Bassler, B. L. (2016) Quorum sensing signal-response systems in Gram-negative bacteria. *Nat. Rev. Microbiol.* *14*, 576-588.
15. Gallagher, L. A., McKnight, S. L., Kuznetsova, M. S., Pesci, E. C., and Manoil, C. (2002) Functions required for extracellular quinolone signaling by *Pseudomonas aeruginosa*. *J. Bacteriol.* *184*, 6472-6480.
16. Xiao, G., Deziel, E., He, J., Lepine, F., Lesic, B., Castonguay, M. H., Milot, S., Tampakaki, A. P., Stachel, S. E., and Rahme, L. G. (2006) MvfR, a key *Pseudomonas aeruginosa* pathogenicity LTTR-class regulatory protein, has dual ligands. *Mol. Microbiol.* *62*, 1689-1699.
17. Aleksic, I., Segan, S., Andric, F., Zlatovic, M., Moric, I., Opsenica, D. M., and Senerovic, L. (2017) Long-Chain 4-Aminoquinolines as Quorum Sensing Inhibitors in *Serratia marcescens* and *Pseudomonas aeruginosa*. *ACS Chem. Biol.* *12*, 1425-1434.
18. Zender, M., Klein, T., Henn, C., Kirsch, B., Maurer, C. K., Kail, D., Ritter, C., Dolezal, O., Steinbach, A., and Hartmann, R. W. (2013) Discovery and biophysical characterization of 2-amino-oxadiazoles as novel antagonists of PqsR, an important regulator of *Pseudomonas aeruginosa* virulence. *J. Med. Chem.* *56*, 6761-6774.

19. Gruber, J. D., Chen, W., Parnham, S., Beauchesne, K., Moeller, P., Flume, P. A., and Zhang, Y. M. (2016) The role of 2,4-dihydroxyquinoline (DHQ) in *Pseudomonas aeruginosa* pathogenicity. *PeerJ* 4, e1495.
20. Collier, D. N., Anderson, L., McKnight, S. L., Noah, T. L., Knowles, M., Boucher, R., Schwab, U., Gilligan, P., and Pesci, E. C. (2002) A bacterial cell to cell signal in the lungs of cystic fibrosis patients. *FEMS Microbiol. Lett.* 215, 41-46.
21. Massai, F., Imperi, F., Quattrucci, S., Zennaro, E., Visca, P., and Leoni, L. (2011) A multitask biosensor for micro-volumetric detection of N-3-oxo-dodecanoyl-homoserine lactone quorum sensing signal. *Biosens. Bioelectron.* 26, 3444-3449.
22. Duan, K., and Surette, M. G. (2007) Environmental regulation of *Pseudomonas aeruginosa* PAO1 Las and Rhl quorum-sensing systems. *J. Bacteriol.* 189, 4827-4836.
23. Fletcher, M. P., Diggle, S. P., Crusz, S. A., Chhabra, S. R., Camara, M., and Williams, P. (2007) A dual biosensor for 2-alkyl-4-quinolone quorum-sensing signal molecules. *Environ. Microbiol.* 9, 2683-2693.
24. Šegan, S., Opsenica, D., and Milojković-Opsenica, D. (2019) Thin-layer chromatography in medicinal chemistry. *J. Liq. Chromatogr. R. T.* 9-10, 238-248.
25. Pearson, J. P., Van Delden, C., and Iglewski, B. H. (1999) Active efflux and diffusion are involved in transport of *Pseudomonas aeruginosa* cell-to-cell signals. *J. Bacteriol.* 181, 1203-1210.
26. Lamarche, M. G., and Deziel, E. (2011) MexEF-OprN efflux pump exports the *Pseudomonas* quinolone signal (PQS) precursor HHQ (4-hydroxy-2-heptylquinoline). *PLoS One* 6, e24310.
27. Mashburn, L. M., and Whiteley, M. (2005) Membrane vesicles traffic signals and facilitate group activities in a prokaryote. *Nature* 437, 422-425.
28. Wang, S., Liu, X., Liu, H., Zhang, L., Guo, Y., Yu, S., Wozniak, D. J., and Ma, L. Z. (2015) The exopolysaccharide Psl-eDNA interaction enables the formation of a biofilm skeleton in *Pseudomonas aeruginosa*. *Environ. Microbiol. Rep.* 7, 330-340.
29. Arora, S. K., Neely, A. N., Blair, B., Lory, S., and Ramphal, R. (2005) Role of motility and flagellin glycosylation in the pathogenesis of *Pseudomonas aeruginosa* burn wound infections. *Infect. Immun.* 73, 4395-4398.
30. van der Plas, M. J., Bhongir, R. K., Kjellstrom, S., Siller, H., Kasetty, G., Morgelin, M., and Schmidtchen, A. (2016) *Pseudomonas aeruginosa* elastase cleaves a C-terminal peptide from human thrombin that inhibits host inflammatory responses. *Nat. Commun.* 7, 11567-11573.
31. Glessner, A., Smith, R. S., Iglewski, B. H., and Robinson, J. B. (1999) Roles of *Pseudomonas aeruginosa* las and rhl quorum-sensing systems in control of twitching motility. *J. Bacteriol.* 181, 1623-1629.
32. Daniels, R., Vanderleyden, J., and Michiels, J. (2004) Quorum sensing and swarming migration in bacteria. *FEMS Microbiol. Rev.* 28, 261-289.
33. Pearson, J. P., Pesci, E. C., and Iglewski, B. H. (1997) Roles of *Pseudomonas aeruginosa* las and rhl quorum-sensing systems in control of elastase and rhamnolipid biosynthesis genes. *J. Bacteriol.* 179, 5756-5767.
34. Martinelli, D., Grossmann, G., Sequin, U., Brandl, H., and Bachofen, R. (2004) Effects of natural and chemically synthesized furanones on quorum sensing in *Chromobacterium violaceum*. *BMC Microbiol.* 4, 25-35.
35. Diggle, S. P., Winzer, K., Chhabra, S. R., Worrall, K. E., Camara, M., and Williams, P. (2003) The *Pseudomonas aeruginosa* quinolone signal molecule overcomes the cell density-dependency of the quorum sensing hierarchy, regulates rhl-dependent genes at the onset of stationary phase and can be produced in the absence of LasR. *Mol. Microbiol.* 50, 29-43.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
36. Soukarieh, F., Williams, P., Stocks, M. J., and Camara, M. (2018) Pseudomonas aeruginosa Quorum Sensing Systems as Drug Discovery Targets: Current Position and Future Perspectives. *J. Med. Chem.* *61*, 10385-10402.
 37. Le Berre, R., Nguyen, S., Nowak, E., Kipnis, E., Pierre, M., Ader, F., Courcol, R., Guery, B. P., Faure, K., and Pyopneumagen, G. (2008) Quorum-sensing activity and related virulence factor expression in clinically pathogenic isolates of Pseudomonas aeruginosa. *Clin. Microbiol. Infect.* *14*, 337-343.
 38. Ilangovan, A., Fletcher, M., Rampioni, G., Pustelny, C., Rumbaugh, K., Heeb, S., Camara, M., Truman, A., Chhabra, S. R., Emsley, J., and Williams, P. (2013) Structural basis for native agonist and synthetic inhibitor recognition by the Pseudomonas aeruginosa quorum sensing regulator PqsR (MvfR). *PLoS Pathog.* *9*, e1003508.
 39. Schrödinger® official Site, knowledge base. <https://http://www.schrodinger.com/kb/571> (Jun 10, 2019), Article ID: 571.
 40. Xu, N., Yu, S., Moniot, S., Weyand, M., and Blankenfeldt, W. (2012) Crystallization and preliminary crystal structure analysis of the ligand-binding domain of PqsR (MvfR), the Pseudomonas quinolone signal (PQS) responsive quorum-sensing transcription factor of Pseudomonas aeruginosa. *Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun.* *68*, 1034-1039.
 41. Kitao, T., Lepine, F., Babloui, S., Walte, F., Steinbacher, S., Maskos, K., Blaesse, M., Negri, M., Pucci, M., Zahler, B., Felici, A., and Rahme, L. G. (2018) Molecular Insights into Function and Competitive Inhibition of Pseudomonas aeruginosa Multiple Virulence Factor Regulator. *MBio* *9*, e02158.
 42. Clinical and Laboratory Standards Institute (2012). M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard: 9th ed. CLSI, W. P.
 43. Merritt, J. H., Kadouri, D. E., and O'Toole, G. A. (2005) Growing and analyzing static biofilms. *Curr. Protoc. Microbiol. Chapter 1*, Unit 1B 1.
 44. O'Loughlin, C. T., Miller, L. C., Siryaporn, A., Drescher, K., Semmelhack, M. F., and Bassler, B. L. (2013) A quorum-sensing inhibitor blocks Pseudomonas aeruginosa virulence and biofilm formation. *Proc. Natl. Acad. Sci. U. S. A.* *110*, 17981-17986.
 45. Ohman, D. E., Cryz, S. J., and Iglewski, B. H. (1980) Isolation and characterization of Pseudomonas aeruginosa PAO mutant that produces altered elastase. *J. Bacteriol.* *142*, 836-842.
 46. Ha, D. G., Kuchma, S. L., and O'Toole, G. A. (2014) Plate-based assay for swarming motility in Pseudomonas aeruginosa. *Methods Mol. Biol.* *1149*, 67-72.
 47. Ha, D. G., Kuchma, S. L., and O'Toole, G. A. (2014) Plate-based assay for swimming motility in Pseudomonas aeruginosa. *Methods Mol. Biol.* *1149*, 59-65.
 48. Olejnickova, K., Hola, V., and Ruzicka, F. (2014) Catheter-related infections caused by Pseudomonas aeruginosa: virulence factors involved and their relationships. *Pathog. Dis.* *72*, 87-94.



82x38mm (300 x 300 DPI)